Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Recruiting · NCT06511882 · Registry updated 2026-02-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-02-27 | NCT06511882 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Moffitt Cancer Center | Tampa | United States | 523 |